Ophthalmic Drug Delivery183

Issue No #183 Mar 2026 March 19th, 2026

Issue 183 - Mar 2026

Inside the magazine

THE RETINAL DELIVERY BOTTLENECK: WHY TODAY’S TOOLS WON’T SCALE

Dr David Cottenden

THE RETINAL DELIVERY BOTTLENECK: WHY TODAY’S TOOLS WON’T SCALE

Dr David Cottenden and Benjamin Hatton examine the rapid shift towards cell and gene therapies in ophthalmology, indicated by current pharmaceutical pipelines, and reveal a potential delivery crisis – today’s surgical capacity cannot support what the pipeline demands. Considering this, they explore why a radical rethink of retinal delivery tools could unlock scalable access to the retina.

THE CHALLENGES IN DEVELOPING AND MANUFACTURING CUSTOM OPHTHALMIC INJECTOR DEVICES

Dr Lorna Barron

THE CHALLENGES IN DEVELOPING AND MANUFACTURING CUSTOM OPHTHALMIC INJECTOR DEVICES

Dr Lorna Barron sets out the standards that must be met for effective drug delivery to the eye, characterising both old and new delivery routes that may be used to address the unique challenges of ophthalmic disease.

SHL MEDICAL AND BAYER: A COLLABORATIVE APPROACH TO ADVANCING INTRAVITREAL PAEDIATRIC DOSING

Andreas Kalitzki

SHL MEDICAL AND BAYER: A COLLABORATIVE APPROACH TO ADVANCING INTRAVITREAL PAEDIATRIC DOSING

Andreas Kalitzki, Samuel Wyler and Seda Aksel explain how Bayer and SHL Medical collaborative efforts are enhancing paediatric intravitreal injections through evidence-based dosing strategies and clinically validated therapies using SHL Medical’s Micro Dosing Device technology.

EMPOWERING VISION FOR THE FUTURE: ADVANCED CONTAINMENT SOLUTIONS FOR OPHTHALMIC APPLICATIONS

Dr Linara Cornell

West Pharmaceutical Services

EMPOWERING VISION FOR THE FUTURE: ADVANCED CONTAINMENT SOLUTIONS FOR OPHTHALMIC APPLICATIONS

Dr Linara Cornell, Dr Manali Potnis and Dr Krishnendu Khan review the current landscape and challenges associated with delivery systems for ophthalmic applications, and how West Pharmaceutical Services plays a critical role in this specialised industry by providing high quality prefilled syringe components and systems that meet the stringent requirements for these sight-saving therapies.

NOVELIA<sup>®</sup>: ENABLING THE NEXT GENERATION OF PRESERVATIVE-FREE MULTIDOSE OPHTHALMICS

Séverine Duband

NOVELIA^®: ENABLING THE NEXT GENERATION OF PRESERVATIVE-FREE MULTIDOSE OPHTHALMICS

Severine Duband and Natalia Zabala discuss the role of multidose preservative-free eyedroppers in the ophthalmic market, highlighting the advantages of Nemera’s Novelia^® platform, including its non-return valve system, the sustainability of multidose delivery and the platform’s growing success within the Chinese market.

INTRAVITREAL INJECTIONS – WHAT IS CAUSING PATIENTS TO DISCONTINUE THERAPY AND WHY IS IT SO HARD TO FIX?

INTRAVITREAL INJECTIONS – WHAT IS CAUSING PATIENTS TO DISCONTINUE THERAPY AND WHY IS IT SO HARD TO FIX?

Gregg Draudt considers the significant issue of treatment discontinuation in intravitreal therapies, digging into the root causes of poor adherence and what will be required to reverse this trend in a way that caters to the full range of stakeholders, who often have contradictory requirements.

ADDRESSING OCULAR SAFETY CHALLENGES IN ADC DEVELOPMENT

ADDRESSING OCULAR SAFETY CHALLENGES IN ADC DEVELOPMENT

Dr Tina Rogers discusses antibody-drug conjugates and their potential in direct targeting and treatment of cancers, going further to assess the risks of these treatments and how they can be mitigated.

Top